Immunovia´s biomarker signature for the diagnosis of pancreatic cancer now patented in Japan
LUND, Sweden ― Immunovia is delighted to announce the grant by the Japanese Patent Office of a patent for its biomarker signature for the diagnosis of pancreatic cancer. Japanese Patent No. JP 6115801, is the first patent awarded to Immunovia in Japan covering its proprietary IMMray™ PanCan-d test.Immunovia CEO, Mats Grahn, commented “The grant of this Japanese patent is a significant achievement for Immunovia as it provides robust patent protection for our IMMray™ PanCan-d test in an important commercial market. Immunovia is fully committed to bringing to market this proprietary test